Evidence map›Paper›PMID 40083161›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

VEGF-B is a novel mediator of ER stress which induces cardiac angiogenesis via RGD-binding integrins independent of VEGFR1/NRP activities.

Rahul Mallick, Ahmed B Montaser, Henna Komi, Greta Juusola, Annakaisa Tirronen, Erika Gurzeler, Maria Barbiera, Petra Korpisalo, Tetsuya Terasaki, Tiina Nieminen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Gene Therapy for Heart Failure.Journal of cardiovascular translational research · 2026
    Review
  3. Designing Neural Dynamics: From Digital Twin Modeling to Regeneration.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rahul MallickA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Ahmed B MontaserSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Henna KomiA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Greta JuusolaA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Heart Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland.
Annakaisa TirronenA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Erika GurzelerA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Maria BarbieraA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Petra KorpisaloHeart Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland.
Tetsuya TerasakiSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Tiina NieminenA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Seppo Ylä-HerttualaA.I.Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Heart Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland. Electronic address: seppo.ylaherttuala@uef.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular endothelial growth factor B186 (VEGF-B186), a ligand for VEGF receptor 1 (VEGFR1) and neuropilin (NRP), promotes vascular growth in healthy and ischemic myocardium. However, the mechanisms and signaling of VEGF-B186 to support angiogenesis have remained unclear. We studied the effects of VEGF-B186 and its variant, VEGF-B186R127S, which cannot bind to NRPs, using VEGFR1 tyrosine kinase knockout (TK

Indexed as

Endoplasmic Reticulum StressIntegrinsNeovascularization, PhysiologicOligopeptidesVascular Endothelial Growth Factor BVascular Endothelial Growth Factor Receptor-1AngiogenesisAnimalsEndothelial CellsHumansMiceMice, KnockoutMyocardial IschemiaMyocardiumSignal TransductionSwinearginyl-glycyl-aspartic acidIntegrinsOligopeptidesVascular Endothelial Growth Factor BVascular Endothelial Growth Factor Receptor-1angiogenesiscardiac regenerationendoplasmic reticulumERgene therapyintegrinsischemic myocardiumITGA5ITGAVneuropilinNRPstressVEGF-BVEGFR1 tyrosine kinase knockoutXBP1

Identifiers

PMID40083161
PMCPMC12265967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.